Rice Derica W 4

What Happened
Derica W. Rice, a director of Bristol Myers Squibb Co. (BMY), received a grant of 3,996.367 Deferred Share Units on February 1, 2026. The units are reported at $55.05 each for a total reported value of $220,000. This was an award/grant (not an open-market purchase or sale) and reflects director compensation rather than an immediate market-backed equity purchase.

Key Details

• Transaction date: 2026-02-01; Form 4 filed: 2026-02-03 (timely filing).
• Award: 3,996.367 Deferred Share Units @ $55.05 each; total reported value $220,000. (Transaction code: A; derivative security.)
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1 — Each Deferred Share Unit will convert into a share of common stock upon settlement; units become settleable when the reporting person ceases to be a director or at a later date the director specified.
  • F2 — Amounts include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Context
Deferred Share Units are a form of deferred compensation for non-employee directors. They are derivative awards that convert to actual shares at settlement (often upon leaving the board or at a pre-set date), so this grant does not represent an immediate market purchase or sale. Such grants are routine director compensation and should be interpreted as compensation-related, not necessarily a direct signal of personal bullish or bearish trading intent.